Latest Health News

Argenica Therapeutics reports compelling preclinical evidence that its lead candidate ARG-007 significantly reduces brain cell damage and inflammation in moderate traumatic brain injury models, marking a promising step toward new TBI treatments.

Emyria reports sustained and statistically significant improvements in PTSD symptoms and quality of life three months after MDMA-assisted therapy, signaling a potential breakthrough for treatment-resistant patients.

Argenica Therapeutics has reported compelling preclinical data showing ARG-007 significantly reduces brain cell damage and inflammation in moderate traumatic brain injury, matching levels seen in uninjured controls. This reinforces ARG-007’s potential as a breakthrough neuroprotective therapy.

Beamtree Holdings appoints Marek Stepniak as CEO, signaling a strategic push in international markets with a strong leadership hand familiar with the company’s growth trajectory.

Micro-X Limited has requested an immediate voluntary suspension of its shares on the ASX, pending a forthcoming equity raising announcement expected by February 10.

OncoSil Medical has secured authorization for 120 German hospitals to negotiate funding for its pancreatic cancer treatment device, marking a 43% increase from last year and signaling growing acceptance in Germany’s healthcare system.

Aeris Environmental has updated its quarterly cash flow report, confirming ongoing operational cash outflows but expressing confidence in maintaining current cash flow levels while exploring new funding avenues.

Regis Resources has established a $300 million revolving credit facility, replacing its previous term loan to enhance financial flexibility and liquidity amid a strong banking syndicate backing.

Maas Group Holdings has announced a fresh on-market share buyback of up to 10% of its issued capital, signaling strong confidence in its financial health and future prospects.

Viridis Mining and Minerals Limited has requested an immediate voluntary suspension of its shares pending a capital raising announcement, signaling a pivotal moment for the company.

Sandon Capital Investments announces a fully franked 1.4 cents per share dividend for the March quarter, reflecting a robust annualised yield of 6.9% and underpinned by strong portfolio returns of 17.7% for FY2025 to date.

Optiscan Imaging has initiated a pivotal pre-clinical gastrointestinal study in Germany using its first flexible prototype, aiming to revolutionize real-time GI tract imaging and diagnostics.